Drugs / Aumonertinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05810350 | Jan 2023 → Dec 2024 | non-small cell lung carcinoma | Three Gorges Hospital of Chongqing University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aumonertinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05810350 ↗ |
| Route | Oral | “Aumonertinib 165mg orally once daily” NCT05810350 ↗ |